Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35383100/
1 Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada [email protected]. 2 Kastruplægerne, Kastrup, Denmark. 3 Novo Nordisk AS, Søborg, Denmark. 4 Karolinska Institutet, Stockholm, Sweden. 5 Center for...
Conclusions: In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA1c and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice.
Genetic risk score for plasma uric acid levels is associated with early rapid kidney function decline in type 2 diabetes
You do not currently have access to this article. Subscription prices and ordering for this journal Don't already have an Oxford Academic account? Register Genetic risk score for plasma uric...
Conclusions: Elevated plasma UA is an independent risk factor of incident CKD. Furthermore, plasma UA potentially has a causal role in early eGFR loss in T2D patients.
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting - Applied Health Economics and Health Policy
Source : https://link.springer.com/article/10.1007/s40258-022-00726-z
Objective Our objective was to evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus once-daily canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM) uncontrolled with metformin...
Conclusions: At a willingness-to-pay threshold of CAD50,000 per QALY gained, once-weekly semaglutide 1 mg was cost-effective over 40 years versus once-daily canagliflozin 300 mg for the treatment of T2DM in patients failing to maintain glycemic control with metformin alone.
A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35350598/
We assessed physicians' experiences of prescribing once-weekly (OW) semaglutide to patients with type 2 diabetes (T2D) in Canada. Physicians who had prescribed OW semaglutide to ≥2 patients with T2D in...
Conclusion: The survey suggests that physicians are satisfied with the OW semaglutide clinical effects.
Weight Loss Outcomes With Telemedicine During COVID-19
Source : https://www.frontiersin.org/articles/10.3389/fendo.2022.793290/full
BackgroundAmidst the COVID-19 pandemic, telemedicine was rapidly implemented to maintain patient care during quarantine. However, there is little data on how this transition may have impacted weight loss outcomes and...
Conclusion: Patients on anti-obesity medications who were followed for 6 months via video or video plus in-person visits (hybrid) experienced clinically significant weight loss. Median number of AOMs were similar among groups, and the most common AOMs were metformin, semaglutide 1.0 mg, and topiramate. More investigation is required to compare...